News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Meissa Vaccines, a clinical-stage biotech company developing vaccines to prevent viral respiratory infections, has entered into a manufacturing agreement with contract research development organization (CRDMO) Exothera.
Biotechs located in the US received 19% or $7.6 billion more venture financing from 2018-2023 (YTD) for biologic innovator drugs compared to small molecule counterparts, driven by inflation law to drive down prescription drug prices, reveals GlobalData.
Last month, CDMO giant Samsung Biologics revealed it was planning to have its fifth plant operational by April 2025, five months earlier than previously anticipated.